If you’ve ever stood in the pharmacy aisle squinting at the fine print on a birth control prescription, the drospirenone vs levonorgestrel question has probably crossed your mind. Both are synthetic progestins. Both have been on the market for years. But they don’t behave the same way in your body, and the safety differences are real enough that the FDA has issued specific guidance on one of them.
So which is safer? The honest answer is, it depends on you, your medical history, and what tradeoffs you’re willing to accept.
What I tell patients is that "safer" in birth control isn’t a single number. It’s a profile, and the profile that’s safest for your 22-year-old sister might not be the one that’s safest for you at 38 with mildly elevated blood pressure.
The Quick Background on Each Progestin
Levonorgestrel is one of the oldest synthetic progestins still in wide use. You’ll find it in combination pills like Levora and Seasonique, in the Mirena and Kyleena IUDs, and in the Plan B emergency contraceptive. It’s been studied for decades, and the safety data is deep.
Drospirenone is newer, derived from spironolactone (a potassium-sparing diuretic used for blood pressure and acne). It shows up in Yaz, Yasmin, Beyaz, and Slynd. Because of its spironolactone roots, drospirenone has mild anti-androgen and anti-mineralocorticoid effects, which is why dermatologists sometimes prefer it for patients dealing with hormonal acne or PMDD.
That chemistry difference is the whole story in the drospirenone vs levonorgestrel debate.
Blood Clot Risk: The Headline Issue
Here’s where the two part ways. Multiple large studies, including ones reviewed by the FDA, have found that combination pills containing drospirenone carry a higher risk of venous thromboembolism (VTE) than pills containing levonorgestrel.
The numbers, roughly:
- Levonorgestrel combination pills: about 5 to 7 VTE cases per 10,000 women per year
- Drospirenone combination pills: about 9 to 12 VTE cases per 10,000 women per year
- For comparison, non-users: about 1 to 5 per 10,000 per year
- Pregnancy itself: about 20 per 10,000 per year
So pregnancy is still riskier than either pill. But within the drospirenone vs levonorgestrel comparison, levonorgestrel comes out ahead on clot risk by a meaningful margin. A 2011 BMJ study put the relative risk roughly two to three times higher with drospirenone.
That doesn’t make drospirenone unsafe. It makes it riskier in a specific way that matters more for some patients than others.
Potassium and the Kidney Question
Drospirenone’s anti-mineralocorticoid activity means it can raise potassium levels. For a healthy 25-year-old with normal kidneys, that’s not a clinical issue. For someone on an ACE inhibitor, an ARB, spironolactone, or with kidney disease, it can be.
The NIH MedlinePlus monograph on drospirenone specifically flags this interaction. Levonorgestrel doesn’t have this issue at all.
In practice, what I see most often is that prescribers will check a baseline potassium level if a patient on drospirenone is also taking blood pressure medication. Reasonable precaution, not a deal-breaker.
Side Effects Most Patients Actually Notice
The clot risk gets the headlines, but day-to-day side effects drive most pill switches. Here’s the honest breakdown.
Drospirenone tends to produce:
- Less bloating and water retention (the diuretic effect)
- Clearer skin for many patients with hormonal acne
- Improvement in PMDD symptoms
- Slightly higher rates of breast tenderness early on
Levonorgestrel tends to produce:
- More predictable bleeding patterns
- Occasional androgenic effects (oilier skin, mild acne) in sensitive patients
- Less impact on potassium and electrolytes
- A longer track record across age groups and risk profiles
Neither one is a clean win. Patients who do well on one often do poorly on the other, and switching is common in the first six months.
Who Should Probably Avoid Each One
Drospirenone is generally not the first choice if you have kidney disease, adrenal insufficiency, liver disease, a history of clots, a strong family history of VTE, are over 35 and smoke, or are already on potassium-raising medications.
Levonorgestrel is usually avoided in patients with severe androgenic side effects, uncontrolled hormonal acne that hasn’t responded to other treatments, or significant PMDD where drospirenone has clearer benefit. The Mayo Clinic’s overview of combination oral contraceptives is a good reference for the broader contraindications that apply to both.
If you’re weighing progestin-only options instead, the comparison between norethindrone vs drospirenone mini-pills covers a different angle that’s worth reading if estrogen isn’t right for you. And for patients approaching menopause who are thinking about hormone therapy down the line, the estradiol vs conjugated estrogens comparison is a natural next step.
Cost and Access
This is where levonorgestrel has a clear edge. Generic levonorgestrel combination pills have been around for decades and typically run $10 to $25 per month, often less with a discount card. Drospirenone generics exist but tend to run $25 to $60, and brand-name versions like Yaz can still hit $150+ without insurance.
If price is part of your decision, compare prices on generic levonorgestrel and drospirenone at edrugstore.com before you fill anywhere else. The spread between pharmacies for the same generic can be surprisingly wide.
So Which Is Safer?
For the average healthy patient under 35 with no clotting history and no kidney issues, both are reasonable. For patients with cardiovascular risk factors, family history of clots, or kidney concerns, levonorgestrel has the safer profile in the drospirenone vs levonorgestrel comparison. For patients whose biggest issue is hormonal acne or PMDD, drospirenone may be worth the slightly higher clot risk for the quality-of-life gain.
The decision isn’t really "which pill is safer." It’s "which set of tradeoffs fits my body and my life." Bring your full medication list, your blood pressure history, and your family clotting history to that conversation with your prescriber. Ask specifically about VTE risk if you smoke, are over 35, or have a BMI over 30. And if you’ve tried one and it didn’t agree with you, switching to the other is reasonable and common.
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- FDA Drug Safety Communication on drospirenone and blood clots, official VTE risk comparison between progestins.
- FDA postmarket information on drospirenone-containing pills, label changes and risk context.
- MedlinePlus monograph on drospirenone and ethinyl estradiol, potassium and drug interaction warnings.
- BMJ 2011 study on hormonal contraceptives and VTE risk, relative clot risk data across progestins.
- Mayo Clinic overview of combination birth control pills, patient-facing summary of contraindications and benefits.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More